Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Urology | Journal

Back to Journal Articles

Intravesical Chondroitin Sulfate of Little Benefit in Cystitis

Last Updated: June 06, 2012.

 

Treatment not advised as only small benefit seen in women with interstitial cystitis/bladder pain syndrome

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Intravesical sodium chondroitin sulfate is not recommended for the treatment of interstitial cystitis/bladder pain syndrome in women as it produces only minor improvements in symptoms and pain, according to research published in the June issue of Urology.

WEDNESDAY, June 6 (HealthDay News) -- Intravesical sodium chondroitin sulfate is not recommended for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS) in women as it produces only minor improvements in symptoms and pain, according to research published in the June issue of Urology.

J. Curtis Nickel, M.D., of Queen's University in Kingston, Canada, and colleagues conducted a multicenter, randomized, double-blind, parallel-group study involving 98 women with IC/BPS. The women were treated with either eight weekly bladder instillations of 20 mL of 2-percent chondroitin sulfate or 20 mL of inactive control solution.

Eighty-three percent of the women completed the study. The researchers found that, after 11 weeks, 38 percent reported moderate or marked improvement with chondroitin sulfate, compared with 31.3 percent of control patients. Chondroitin-treated patients also exhibited better response using Interstitial Cystitis Symptom Index and visual analog scale pain scores, although the changes were not statistically significant.

"The results from the present small, controlled, randomized clinical trial suggest that intravesical chondroitin sulfate therapy for IC/BPS can result in minor improvements in IC/BPS-related symptoms and pain," the authors write. "However, the magnitude of benefit observed in our small pilot study does not support its use as a monotherapy for this condition."

The study was supported by Watson Pharmaceuticals Inc.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Circulating Tumor Cells Tied to Poor Prognosis in Breast Cancer Next: PCI Has Excellent Outcomes for Younger Adults With CAD

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.